MediciNova (MNOV) Receives Daily Media Impact Score of 0.20
News articles about MediciNova (NASDAQ:MNOV) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MediciNova earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.7137271712527 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of MediciNova (NASDAQ MNOV) traded up $0.03 during midday trading on Friday, reaching $6.54. The company’s stock had a trading volume of 48,935 shares, compared to its average volume of 230,640. MediciNova has a 52 week low of $4.40 and a 52 week high of $7.85.
In other news, Director Yoshio Ishizaka acquired 5,000 shares of the stock in a transaction dated Monday, August 21st. The shares were acquired at an average cost of $5.17 per share, for a total transaction of $25,850.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at approximately $25,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 15.20% of the company’s stock.
MediciNova Company Profile
Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).
Receive News & Ratings for MediciNova Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.